Squarepoint Ops LLC Cel Sci Corp Transaction History

Squarepoint Ops LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.63 - $3.08 $18,443 - $34,850	11,315 New	11,315 $21,000
Q2 2022 Aug 15, 2022	SELL	$2.58 - $4.99 $162,632 - $314,549	-63,036 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.93 - $7.7 $27,832 - $54,531	7,082 Added 12.66%	63,036 $248,000
Q4 2021 Feb 14, 2022	BUY	$7.1 - $12.82 $397,273 - $717,330	55,954 New	55,954 $397,000
Q1 2021 May 17, 2021	SELL	$12.0 - $27.64 $178,320 - $410,730	-14,860 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$11.05 - $16.62 $164,203 - $246,973	14,860 New	14,860 $173,000
Q1 2020 May 15, 2020	SELL	$7.54 - $17.05 $118,951 - $268,980	-15,776 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$6.71 - $9.55 $105,856 - $150,660	15,776 New	15,776 $144,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.